Reports
Global Parkinson’s Disease Drugs Market Share, Forecast: By Drug Class: MAO-B Inhibitors, Levodopa, COMT Inhibitors, Dopamine Agonists, Anticholinergics, Others; By Route of Administration: Oral, Injection, Transdermal; By Distribution Channel: Hospital Pharmacies, Others; By End Use; Regional Analysis; Competitive Landscape; 2024-2032
Global Parkinson’s Disease Drugs Market Outlook
The global Parkinson’s disease drugs industry is expected to grow at a CAGR of about 7.9% in the forecast period of 2024-2032 to reach a value of around USD 9.78 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Europe Leading the Parkinson’s Disease Drugs Market
The availability of proper health facilities, pharmaceutical options, diagnostic labs, and skilled personnel like neurologists can improve the detection of Parkinson’s disease. Europe, followed by North America, are at the forefront of this market because of the presence of the above facilities. This is further bolstered by government funding for research and growing health awareness is expected to further improve the market for these drugs. In Asia Pacific, the growth rate for Parkinson’s disease drugs is expected to be high in the forecast period 2024-2032 because of the growing ageing population in Japan and China. Furthermore, with improving healthcare networks in Asia Pacific, the market is further expected to rise in the coming years.
Parkinson’s Disease Drugs: Market Segmentation
Parkinson’s disease is a neurogenerative disease which affects motor capabilities. It generally occurs in senior citizens and the symptoms include shaking of limbs, stiffness, and walking and speech difficulty. This is a result of nerve damage because of which the dopamine levels in the brain can drop, leading to this disease. Since there are inadequate resources for the diagnosis of this disease, the disease often goes undetected till a later stage.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The Parkinson’s disease drugs market can be segmented by drug class into:
- MAO-B Inhibitors
- Levodopa
- COMT Inhibitors
- Dopamine Agonists
- Anticholinergics
- Others
It may be differentiated by route of administration into:
- Oral
- Injection
- Transdermal
It may be divided on the basis of distribution channels into:
- Hospital Pharmacies
- Retail Pharmacies
- Online
- Others
The market may be differentiated on the basis of end-use as:
- Hospitals
- Clinics
- Others
The regional markets for Parkinson’s disease drugs can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Generic Drugs Bolstering the Market Growth
For Parkinson’s disease, the first response is usually medication. As generic drugs gain a stronger foothold, especially in developing countries, companies can expect to expand into wider markets. With a rise in skilled professionals like neurologists and lab technicians, the detection rate of the disease will also increase, in turn increasing the market for drugs. Stronger drug pipelines of pharmaceutical companies will positively affect the market too. Over time, a rise in the sales of drugs is expected because of increasing presence of diagnostic labs and chemist shops. Growing health awareness and improving healthcare facilities, especially in developing countries is expected to positively impact the growth of the market.
Key Industry Players in the Global Parkinson’s Disease Drugs Market
The report gives a detailed analysis of the following key players in the global Parkinson’s disease drugs industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Pfizer Inc.
- Medtronic plc
- GlaxoSmithKline plc.
- AbbVie Inc.
- Novartis AG
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug Class, Route of Administration, Distribution Channel, End Use, Region |
| Breakup by Drug Class | MAO-B Inhibitors, Levodopa, COMT Inhibitors, Dopamine Agonists, Anticholinergics, Others |
| Breakup by Route of Administration | Oral, Injection, Transdermal |
| Breakup by Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online, Others |
| Breakup by End Use | Hospital, Clinics, Others |
| Breakup by Region | North America, Latin America, Europe, Middle East and Africa, Asia Pacific |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Pfizer Inc., Medtronic plc, GlaxoSmithKline plc., AbbVie Inc., Novartis AG, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Parkinson’s Disease Drug Market Analysis
8.1 Key Industry Highlights
8.2 Global Parkinson’s Disease Drug Historical Market (2018-2023)
8.3 Global Parkinson’s Disease Drug Market Forecast (2024-2032)
8.4 Global Parkinson’s Disease Drug Market by Drug Class
8.4.1 MAO-B Inhibitors
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2023)
8.4.1.3 Forecast Trend (2024-2032)
8.4.2 Levodopa
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2023)
8.4.2.3 Forecast Trend (2024-2032)
8.4.3 COMT Inhibitors
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2023)
8.4.3.3 Forecast Trend (2024-2032)
8.4.4 Dopamine Agonists
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2023)
8.4.4.3 Forecast Trend (2024-2032)
8.4.5 Anticholinergics
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2018-2023)
8.4.5.3 Forecast Trend (2024-2032)
8.4.6 Others
8.5 Global Parkinson’s Disease Drug Market by Route of Administration
8.5.1 Oral
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2023)
8.5.1.3 Forecast Trend (2024-2032)
8.5.2 Injection
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2023)
8.5.2.3 Forecast Trend (2024-2032)
8.5.3 Transdermal
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2023)
8.5.3.3 Forecast Trend (2024-2032)
8.6 Global Parkinson’s Disease Drug Market by Distribution Channel
8.6.1 Hospital Pharmacies
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2023)
8.6.1.3 Forecast Trend (2024-2032)
8.6.2 Retail Pharmacies
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2023)
8.6.2.3 Forecast Trend (2024-2032)
8.6.3 Online
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2023)
8.6.3.3 Forecast Trend (2024-2032)
8.6.4 Others
8.7 Global Parkinson’s Disease Drug Market by End Use
8.7.1 Hospital
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2023)
8.7.1.3 Forecast Trend (2024-2032)
8.7.2 Clinics
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2023)
8.7.2.3 Forecast Trend (2024-2032)
8.7.3 Others
8.8 Global Parkinson’s Disease Drug Market by Region
8.8.1 Market Share
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
9.2.3 Breakup by Country Kingdom
9.2.3.1 United
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2023)
9.3.2 Forecast Trend (2024-2032)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2023)
9.4.2 Forecast Trend (2024-2032)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2023)
9.5.2 Forecast Trend (2024-2032)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Pfizer, Inc.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Medtronic plc
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 GlaxoSmithKline plc.
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 AbbVie Inc.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Novartis AG
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Parkinson’s Disease Drug Market: Key Industry Highlights, 2018 and 2032
2. Global Parkinson’s Disease Drug Historical Market: Breakup by Drug Class (USD Million), 2018-2023
3. Global Parkinson’s Disease Drug Market Forecast: Breakup by Drug Class (USD Million), 2024-2032
4. Global Parkinson’s Disease Drug Historical Market: Breakup by Route of Administration (USD Million), 2018-2023
5. Global Parkinson’s Disease Drug Market Forecast: Breakup by Route of Administration (USD Million), 2024-2032
6. Global Parkinson’s Disease Drug Historical Market: Breakup by Distribution Channel (USD Million), 2018-2023
7. Global Parkinson’s Disease Drug Market Forecast: Breakup by Distribution Channel (USD Million), 2024-2032
8. Global Parkinson’s Disease Drug Historical Market: Breakup by End Use (USD Million), 2018-2023
9. Global Parkinson’s Disease Drug Market Forecast: Breakup by End Use (USD Million), 2024-2032
10. Global Parkinson’s Disease Drug Historical Market: Breakup by Region (USD Million), 2018-2023
11. Global Parkinson’s Disease Drug Market Forecast: Breakup by Region (USD Million), 2024-2032
12. North America Parkinson’s Disease Drug Historical Market: Breakup by Country (USD Million), 2018-2023
13. North America Parkinson’s Disease Drug Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Europe Parkinson’s Disease Drug Historical Market: Breakup by Country (USD Million), 2018-2023
15. Europe Parkinson’s Disease Drug Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Asia Pacific Parkinson’s Disease Drug Historical Market: Breakup by Country (USD Million), 2018-2023
17. Asia Pacific Parkinson’s Disease Drug Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Latin America Parkinson’s Disease Drug Historical Market: Breakup by Country (USD Million), 2018-2023
19. Latin America Parkinson’s Disease Drug Market Forecast: Breakup by Country (USD Million), 2024-2032
20. Middle East and Africa Parkinson’s Disease Drug Historical Market: Breakup by Country (USD Million), 2018-2023
21. Middle East and Africa Parkinson’s Disease Drug Market Forecast: Breakup by Country (USD Million), 2024-2032
22. Global Parkinson’s Disease Drug Market Structure
Key Questions Answered in the Report
The global Parkinson’s disease drugs market is projected to grow at a CAGR of 7.9% between 2024 and 2032.
The major drivers of the market include the rise in the sales of drugs, increasing presence of diagnostic labs and chemist shops, growing health awareness, improving healthcare facilities, government funding for research, and growing ageing population.
A rise in skilled professionals like neurologists and lab technicians and stronger drug pipelines of pharmaceutical companies are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The Parkinson’s disease drugs market can be segmented by drug class into MAO-B inhibitors, levodopa, COMT inhibitors, dopamine agonists, and anticholinergics, among others.
It may be differentiated by route of administration into oral, injection, and transdermal.
The distribution channels include hospital pharmacies, retail pharmacies, and online, among others.
The end-uses are hospitals and clinics, among others.
The major players in the industry are Pfizer Inc., Medtronic plc, GlaxoSmithKline plc., AbbVie Inc., and Novartis AG, among others.
Analyst Review
The global Parkinson’s disease drugs market was driven by the rise in skilled professionals like neurologists and lab technicians. Aided by improving healthcare facilities and the growing ageing population, the market is expected to witness further growth in the forecast period of 2024-2032, growing at a CAGR of 7.9%.
EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The Parkinson’s disease drugs market can be segmented by drug class into MAO-B inhibitors, levodopa, COMT inhibitors, dopamine agonists, and anticholinergics, among others. It may be differentiated by route of administration into oral, injection, and transdermal. The distribution channels include hospital pharmacies, retail pharmacies, and online, among others. The end-uses are hospitals and clinics, among others. The major regional markets for Parkinson’s disease drugs are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The major players in the industry are Pfizer Inc., Medtronic plc, GlaxoSmithKline plc., AbbVie Inc., and Novartis AG, among others.
EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER